title: Bacteriophage Therapy: Advances in Formulation Strategies and Human Clinical Trials.
abstract: Recently, a number of phage therapy phase I and II safety trials have been concluded, showing no notable safety concerns associated with the use of phage. Though hurdles for efficient treatment remain, these trials hold promise for future phase III clinical trials. Interestingly, most phage formulations used in these clinical trials are straightforward phage suspensions, and not much research has focused on the processing of phage cocktails in specific pharmaceutical dosage forms. Additional research on formulation strategies and the stability of phage-based drugs will be of key importance, especially with phage therapy advancing toward phase III clinical trials.
authors.affiliation: Laboratory of Gene Technology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium; email: dieter.vandenheuvel@biw.kuleuven.be , rob.lavigne@biw.kuleuven.be.
authors.forename: Dieter
authors.initials: D
authors.lastname: Vandenheuvel
authors.affiliation: Laboratory of Gene Technology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium; email: dieter.vandenheuvel@biw.kuleuven.be , rob.lavigne@biw.kuleuven.be.
authors.forename: Rob
authors.initials: R
authors.lastname: Lavigne
authors.affiliation: Nestlé Research Center, Nestec Ltd., Vers-chez-les-Blanc, 1000 Lausanne 26, Switzerland; email: harald.bruessow@rdls.nestle.com.
authors.forename: Harald
authors.initials: H
authors.lastname: Brüssow
mesh_terms: D001435:Bacteriophages / Q000235:genetics / Q000502:physiology*; D001691:Biological Therapy / Q000295:instrumentation / Q000379:methods / Q000639:trends*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans
keywords: bacteriophage therapy; biotechnology; phage therapy clinical trial; pharmaceutical dosage formulation; stability